Physician profile
Chris Kos
NPI 1548747256
$2,370.68
in general payments reported to CMS, 2019-2025
14 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,004 · 2024: $805 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.77 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $574.75 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $567.97 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $293.91 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.59 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $161.44 | 2023 | Auvelity |
| Alkermes, INC. | $133.75 | 2023 | Lybalvi, Aristada |
| Janssen Scientific Affairs, LLC | $90.37 | 2025 | Spravato |
| Amgen INC. | $77.60 | 2023 | Repatha |
| Indivior INC. | $62.95 | 2023 | Perseris |
| Neurocrine Biosciences, INC. | $55.18 | 2024 | Ingrezza |
| Lundbeck LLC | $34.02 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $25.57 | 2023 | Trintellix |
| Corium, LLC | $23.85 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $17.73 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Kos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.